Biotech and Pharma

Mylan quarterly revenue misses estimates, shares fall

Key Points
  • Drugmaker Mylan missed Wall Street estimates for quarterly revenue.
  • Results were hurt by restructuring at its Morgantown plant in West Virginia and a stronger dollar.
  • Revenue from its North America business fell 6% to $922.9 million and missed estimates of $952.43 million, largely due to increased competition.
Heather Bresch, CEO of Mylan.
Adam Jeffery | CNBC

Drugmaker Mylan missed Wall Street estimates for quarterly revenue on Tuesday, hurt by restructuring at its Morgantown plant in West Virginia and a stronger dollar, sending its shares down 4.5%.

Revenue from its North America business fell 6% to $922.9 million and missed estimates of $952.43 million, largely due to increased competition.

Total revenue fell 7% to $2.50 billion and missed estimates of $2.69 billion, according to IBES data from Refinitiv.

The company reported a net loss of $25 million, or 5 cents per share, in the first quarter ended March 31, compared with profit of $87.1 million, or 17 cents per share, a year earlier.

Excluding items, the company earned 82 cents per share and beat expectations of 79 cents per share.

Next Article
Key Points
  • Pioneer Natural Resources beat Wall Street estimates for quarterly profit.
  • The company also said it sold its Eagle Ford and remaining assets in South Texas to become a pure-play Permian basin producer.
  • The deal will help Pioneer achieve its aim to solely focus on the Permian basin of West Texas and Eastern New Mexico to produce energy.